Program areas at FIND
Antimicrobial Resistance (EXPENSES $5,623,858) AADAUC: Assessment AMR Dx and Abx in-country AMR CARBX Accelerator AMR Dx Accelerator AMR Molecular Assay AMR Neonatal Sepsis South Africa AMR Programme management AMR Score Card AMR STI WP2 Clinical Trial Site Development AMR Strategy AMR Surveillance digital toolkit - Kenya and Nepal COVID-19 Genomic surveillance CRP demonstration studies Cumulative Antibiograms EU ValueDx GoNoGo: Stewardship of new Gonorrhoea antibiotics HAMRAS: HAI surveillance and AMS Improve AMS practices at PHC: POC and digital NEOAMR: Neonatal Sepsis Diagnostic AMR Prevention Rapid Dual LFA for GN and CT Simplified Blood Culture WHO - FIND AMR In country WHO AMR Secondment Complex Humanitarian Environments (EXPENSES $273,112) Conflict Affected Settings Laboratory Strengthenin Partnership Building Hepatitis and HIV (EXPENSES $28,603) Global Policy HCV self-test Impact (EXPENSES $1,487,563) GAP Impact Network Impact general management Impact Information Foundational Value of Diagnostics Malaria and Fever (EXPENSES $3,638,444) Data from RDT lot-testing at time of procurement Dengue evaluation study Diagnosis for UHC Tracker Digital ETAT Evidence for non-invasive malaria tests Evidence Severity Field evaluation of a POC hematology platform FIND-GAVI collaboration FIND-GAVI collaboration (landscaping activities) FIND-GAVI collaboration (Meningo evaluations) G6PD biosensor implementation HS-RDT HRP2 impact studies Innovation Platform Malaria and Fever programme management Malaria specimen bank P. vivax malaria - serology tests POC hematology PvSTATEM: digital tool for PvSeroTAT Temperature stability Typhoid diagnostic Vital signs triage toolkit Medical Affairs (EXPENSES $3,342,484) Billing of specimen dstribution Biobanking Development Clinical Affairs general management Clinical Trial unit general management Clinical-Regulatory-QMS COVID-19 (CTU) Diagnostics center of excellence Medical Affairs general management Medical Affairs portfolio management Program coordination and supervision Regulatory unit general management Specimen bank unit general management Neglected Tropical Diseases (EXPENSES $5,142,868) BU LAMP BU RDT development Chagas disease RDT development CUIDA Chagas Evaluation of onchocerciasis diagnostics Evaluation of RDTs for chronic Chagas disease HAT (sleeping sickness) elimination HAT elimination (Angola) HAT elimination (Chad) HAT elimination (DRC) HAT elimination (Guinea) HAT elimination (South Sudan) HAT elimination (Uganda) HAT Kenya HAT RDT development NTD biobanking collection in Ghana NTD programme management Schistosomiasis CAA RDT development Visceral leishmaniasis Ag RDT development Visceral leishmaniasis elimination Non-Communicable Diseases (EXPENSES $1,975,355) ACCEDE: Access to CGMs for Equity in Diabetes Mgt Access to Cardiometabolic Management Access to Glucose Measurement Through DxConnect Diabetes Management Education Diabetes Quality Assurance Evidences Digital Education for Pharmacists - Mclinica HbA1c POC h2h Comparison NCD Programme Management New Tech for Diabetes & Cardiometabolic Conditions Pandemic Threats (EXPENSES $7,439,585) AgRDT Demonstration study in Botswana COVID-19 Eval Antigen RDTs COVID-19 external quality assessment molecular COVID-19 Mobile Labs COVID-19 Surveillance data digital tool-kit COVID-19 test and treat Diagnostic Network Optimization OB surveillance DXOD: Diagnostics for outbreak diseases Taskforce Evaluation of COVID-19 Molecular POC tests External Quality Assessment CV Antigen Testing G7-G20 Engagement Independent Evaluation of Ebola RDTs Marburg RDT product development OB Lassa Fever Response OB Lassa Fever Response-Dissemination and training OB preparedness and response in West Africa Pandemic Threats programme management PATH/WHO/FIND COVID-19 diagnostic benchmarking PT market assessment and landscape Test evaluation network for OB disease diagnostics Yellow Fever RDT R&D and Evaluation Surveillance (EXPENSES $265,435) Community-led outbreak Prep and response Surveillance general management Women's Health (EXPENSES $1,319,584) Cervical Cancer Elimination Cervical Cancer Elimination (Access) Cervical Cancer Elimination (Community) Cervical Cancer Elimination (Digital) Cervical Cancer Elimination (R&D Evaluation) Cervical Cancer Elimination (R&D Regulatory) HPV Cervical Cancer screening in Viet Nam WH programme management
Who funds Foundation for Innovative New Diagnostics (FIND)
Grants from foundations and other nonprofits
Personnel at FIND
| Name | Title | Compensation | Date of data |
|---|
| Bill Rodriguez | Chief Executive Officer | | 2024-06-12 |
| Ifedayo Adetifa | Chief Transformation Officer and Chief Executive Officer | | 2024-11-20 |
| Sergio Carmona | Acting Chief Executive Officer and Chief Medical Officer | $328,189 | 2024-06-12 |
| Norma Torres | Chief Operations Officer | | 2023-11-15 |
| Marta Fernandez Suarez | Chief Technology Officer | $329,322 | 2024-06-12 |
| ...and 29 more key personnel |
Financials for FIND
| Revenues | FYE 12/2023 | FYE 12/2022 | % Change |
|---|
| Total grants, contributions, etc. | $86,961,801 | $142,991,509 | -39.2% |
| Program services | $0 | $0 | - |
| Investment income and dividends | $3,411,063 | $961,319 | 254.8% |
| Tax-exempt bond proceeds | $0 | $0 | - |
| Royalty revenue | $0 | $0 | - |
| Net rental income | $0 | $0 | - |
| Net gain from sale of non-inventory assets | $0 | $0 | - |
| Net income from fundraising events | $0 | $0 | - |
| Net income from gaming activities | $0 | $0 | - |
| Net income from sales of inventory | $0 | $0 | - |
| Miscellaneous revenues | $239,613 | $295,241 | -18.8% |
| Total revenues | $90,612,477 | $144,248,069 | -37.2% |
Organizations like FIND
| Organization | Type | Location | Revenue |
|---|
| American College of Cardiology Foundation (ACCF) | 501(c)(3) | Washington, DC | $124,168,198 |
| Crohn's and Colitis Foundation (CCFA) | 501(c)(3) | New York, NY | $81,765,248 |
| Cure 4 the Kids Foundation | 501(c)(3) | Las Vegas, NV | $41,796,359 |
| Brown Neurology | 501(c)(3) | Providence, RI | $43,048,918 |
| Ahrc Nyc | 501(c)(3) | New York, NY | $308,090,587 |
| Orthopaedic Foundation | 501(c)(3) | Los Angeles, CA | $24,443,595 |
| Elizabeth Glaser Pediatric Aids Foundation | 501(c)(3) | Washington, DC | $162,295,489 |
| American Society of Hematology (ASH) | 501(c)(3) | Washington, DC | $108,333,795 |
| Men's Health Foundation | 501(c)(3) | Los Angeles, CA | $51,846,184 |
| Lupus Research Alliance (ALR) | 501(c)(3) | New York, NY | $50,861,497 |
Data update history
November 20, 2024
Updated personnel
Identified 5 new personnel
June 12, 2024
Updated personnel
Identified 2 new personnel
January 7, 2024
Posted financials
Added Form 990 for fiscal year 2022
January 6, 2024
Updated personnel
Identified 8 new personnel
Nonprofit Types
Grantmaking organizationsCorporate foundationsDisease research fundraisersProfessional associationsDisease-focused nonprofitsCharities
Issues
HealthDiseases and disordersMedical disciplines
Characteristics
Provides grantsConducts researchOperates internationallyReceives government fundingTax deductible donationsAccepts online donations
General information
- Address
- Chemin Du Pommier 40
- Switzerland, 00000
- Website URL
- finddx.org/
IRS details
- EIN
- 98-0407553
- Fiscal year end
- December
- Taxreturn type
- Form 990
- Year formed
- 2003
- Eligible to receive tax-deductible contributions (Pub 78)
- Yes
Categorization
- NTEE code, primary
- G90: Medical Disciplines
- NAICS code, primary
- 813212: Health and Disease Research Fundraising Organizations
- Parent/child status
- Independent
Free account sign-up
Want updates when FIND has new information, or want to find more organizations like Foundation for Innovative New Diagnostics (FIND)?
Create free Cause IQ account